BioSpace News Archive

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors.

23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced that it will report financial results for the fiscal year 2023 second quarter after the market closes on Monday, November 7, 2022.

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2022 at 5:00 PM ET to report its third quarter 2022 financial results and provide a corporate update.

Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced new real-world data identifying demographic characteristics and comorbidities of patients with narcolepsy.

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.

IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes on Tuesday, November 8, 2022 at 12:10 p.m. ET.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022.

NyxoahSA announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

Ligand Pharmaceuticals Incorporated announced the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc., was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination.